ENTERA BIO LTD

ENTXNASDAQ

🏆 #2747 by market capEarnings Nov 13US Equity

$2.76▼ $0.22 (−8.00%)

Live

1h▼ 2.3%

24h▼ 8.0%

7d▼ 1.6%

14d▼ 8.5%

30d▲ 67.3%

1y▲ 46.4%

🏦Market Cap

$475M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

4.0%

Thin

💵FCF Margin

—

⚖️P/S Ratio

641.0x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $2.74 – $2.80
52-Week Range: $0.91 – $4.20
Volume: $2.91B
Avg Volume: $2.62B
Shares Outstanding: 172.3M
Next Earnings: Sep 16, 2026

Fundamentals Snapshot

Annual Revenue: $42,000
Last Q Revenue: $11,018
P/E Ratio: —
P/S Ratio: 641.0x
EPS (TTM): $-0.26
Dividend Yield: —

Why Investors Own ENTX

✓High-growth profile — revenue up +39.6% YoY with expanding US Equity exposure.
✓Healthy economics — 51% gross margin and 29% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$42,000▲ +46.3% YoY

Gross Margin (TTM)

50.9%▲ +3.5% YoY

Operating Income (TTM)

$12,222▲ +46.3% YoY

Free Cash Flow (TTM)

$12,222▲ +46.3% YoY

About ENTERA BIO LTD

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

🦦